Pediatric Hematology and Oncology, University Children's Hospital Giessen, Hesse, Germany.
Swedish Covenant Hospital Department of Gynecology, Chicago, IL, U.S.A.
Anticancer Res. 2022 Jan;42(1):45-52. doi: 10.21873/anticanres.15455.
BACKGROUND/AIM: Fatigue and asthenia are common in patients with cancer; and identifying the cause as drug toxicity versus cancer progression is difficult, particularly in clinical trials without control arms.
We carried out a systematic literature review of fatigue in placebo arms of randomized cancer trials reported in PubMed from 2000 to 2021.
Fatigue/asthenia were reported in 100 out of 134 placebo cohorts, and the average of reported frequencies was 22.8%, with a range of 0-83%. Grade 3 or higher fatigue/asthenia was reported in 2.3% (0-17%). Fatigue/asthenia was positively correlated with nausea (R=0.683) Conclusion: For detection of drug toxicity, observations should be flagged when they are higher than the maximum reported in the placebo arm, and the assessment should be supplemented by comparing observations in early oncology trials to literature placebo arms, including both sample sizes and event numbers.
背景/目的:疲劳和乏力是癌症患者常见的症状;而要确定其原因是药物毒性还是癌症进展,这很困难,尤其是在没有对照组的临床试验中。
我们对 2000 年至 2021 年期间在 PubMed 上报道的随机癌症试验安慰剂组中的疲劳进行了系统的文献回顾。
在 134 个安慰剂队列中有 100 个报告了疲劳/乏力,报告的频率平均为 22.8%,范围为 0-83%。报告了 3 级或更高等级的疲劳/乏力为 2.3%(0-17%)。疲劳/乏力与恶心呈正相关(R=0.683)。
为了检测药物毒性,当观察结果高于安慰剂组报告的最大值时,应标记观察结果,并且应通过将早期肿瘤学试验的观察结果与文献中的安慰剂组进行比较来补充评估,包括样本量和事件数量。